HIV-1 Neutralizing Antibodies: Understanding Nature's Pathways

Journal Article

The development of an effective vaccine has been hindered by the enormous diversity of human immunodeficiency virus-1 (HIV-1) and its ability to escape a myriad of host immune responses. In addition, conserved vulnerable regions on the HIV-1 envelope glycoprotein are often poorly immunogenic and elicit broadly neutralizing antibody responses (BNAbs) in a minority of HIV-1-infected individuals and only after several years of infection. All of the known BNAbs demonstrate high levels of somatic mutations and often display other unusual traits, such as a long heavy chain complementarity determining region 3 (CDRH3) and autoreactivity that can be limited by host tolerance controls. Nonetheless, the demonstration that HIV-1-infected individuals can make potent BNAbs is encouraging, and recent progress in isolating such antibodies and mapping their immune pathways of development is providing new strategies for vaccination. © 2013 John Wiley & Sons A/S 254 1 July 2013 10.1111/imr.12075 Invited Review Invited Reviews Published 2013. This article is a U.S. Government work and is in the public domain in the USA..

Full Text

Duke Authors

Cited Authors

  • Mascola, JR; Haynes, BF

Published Date

  • 2013

Published In

Volume / Issue

  • 254 / 1

Start / End Page

  • 225 - 244

PubMed ID

  • 23772623

Pubmed Central ID

  • 23772623

International Standard Serial Number (ISSN)

  • 0105-2896

Digital Object Identifier (DOI)

  • 10.1111/imr.12075